Prediction of adverse perinatal outcome and the mean time until delivery in twin pregnancies with suspected pre-eclampsia using sFlt-1/PIGF ratio.
Adult
Biomarkers
/ blood
Female
Fetal Growth Retardation
HELLP Syndrome
Humans
Parturition
Placenta Growth Factor
/ blood
Pre-Eclampsia
/ blood
Predictive Value of Tests
Pregnancy
Pregnancy Outcome
Pregnancy Proteins
/ blood
Pregnancy, Twin
/ blood
Retrospective Studies
Time Factors
Vascular Endothelial Growth Factor Receptor-1
/ blood
Young Adult
(Anti-) angiogenic factors
Placental growth factor
Preeclampsia
Soluble fms-like
Twin pregnancies
Tyrosine kinase 1
Journal
Pregnancy hypertension
ISSN: 2210-7797
Titre abrégé: Pregnancy Hypertens
Pays: Netherlands
ID NLM: 101552483
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
27
09
2020
revised:
02
12
2020
accepted:
04
02
2021
pubmed:
2
3
2021
medline:
9
11
2021
entrez:
1
3
2021
Statut:
ppublish
Résumé
An elevated soluble fms-like tyrosine kinase-1 (sFlt-1) / placental growth factor (PlGF) ratio is associated with adverse perinatal outcome (APO) and the mean time until delivery (MTUD) in singleton pregnancies complicated by pre-eclampsia (PE). Data on APO and MTUD prediction in twin pregnancies using sFlt-1/PlGF ratio are scarce. We evaluated the predictive value of the sFlt-1/PIGF ratio regarding APO and MTUD in twin pregnancies with suspected PE and/or HELLP syndrome. This is a single center retrospective cohort study. All twin pregnancies with suspected PE/HELLP and determined sFlt-1/PIGF were included. Composite APO (CAPO) was defined as the presence of at least one of the following outcomes: respiratory distress syndrome (RDS), intubation, admission to neonatal intensive care unit (NICU) and arterial umbilical cord pH value < 7.10. Selective fetal growth restriction (s-FGR) was analyzed separately. For final analysis, 49 twin pregnancies were included. Median sFlt-1/PIGF ratio was not significantly different in patients with CAPO compared to those without (89.45 vs. 62.00, p = 0.669). MTUD was significantly negative correlated with sFlt-1/PIGF ratio (r = -0.409, p < 0.001). For the whole study cohort, ROC analysis revealed no predictive value for sFlt-1/PIGF and CAPO (AUC = 0.618, 95% CI: 0.387-0.849, p = 0.254). However, sFlt-1/PIGF ratio showed a predictive value for s-FGR (AUC = 0.755, 95% CI: 0.545-0.965, p = 0.032). In twin pregnancies with PE and/or HELLP, sFlt-1/PIGF ratio may be helpful for s-FGR prediction and decision-making regarding close monitoring of high-risk patients. However, further prospective studies are warranted to define the role of sFlt-1/PlGF ratio as outcome predictor in twin pregnancies.
Identifiants
pubmed: 33647841
pii: S2210-7789(21)00005-2
doi: 10.1016/j.preghy.2021.02.003
pii:
doi:
Substances chimiques
Biomarkers
0
PGF protein, human
0
Pregnancy Proteins
0
Placenta Growth Factor
144589-93-5
FLT1 protein, human
EC 2.7.10.1
Vascular Endothelial Growth Factor Receptor-1
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
37-43Informations de copyright
Copyright © 2021. Published by Elsevier B.V.